|
Jan. 15, 2025 |
|
|
June. 05, 2026 |
|
|
jRCT2033240611 |
Open-Label, Dose Escalation, Single-dose Study of RV-001 in Subjects with Retinitis Pigmentosa (Phase I/II) |
|
Phase I/II Study for RV-001 |
Katada Yusaku |
||
Restore Vision Inc. |
||
Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo |
||
+81-90-5068-2405 |
||
chiken@restore-vis.com |
||
Katada Yusaku |
||
Restore Vision Inc. |
||
Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo |
||
+81-90-5068-2405 |
||
chiken@restore-vis.com |
Recruiting |
Feb. 01, 2025 |
||
| 45 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
18 years old and up at the time of ICF signature |
||
Diagnosed with an inherited retinal degenerative disease other than non-syndromic Retinitis Pigmentosa or systemic symptoms, such as hearing loss. |
||
| 18age old over | ||
| No limit | ||
Retinitis Pigmentosa |
||
Administration of investigational product |
||
Dose-Limiting Toxicity |
||
| Restore Vision Inc. |
| Keio University Hospital Institutional Review Board | |
| 35 Shinanomachi, Shinjuku-ku, Tokyo | |
| Approval | |
Dec. 27, 2024 |
| Kobe City Medical Center General Hospital Institutional Review Board | |
| 2-1-1, Minatojima-minamimachi, Chuo-ku, Kobe-city, Tokyo | |
| Approval | |
Dec. 27, 2024 |
No |
None |